DSM-Firmenich completes acquisition of postbiotics supplier Adare Biome
The acquisition enhances DSM-Firmenich’s presence in several markets, including early-life nutrition, medical nutrition, and the microbiome market for pet health and animal feed.
Photo © iStockphoto.com
DSM-Firmenich (Kaiseraugst, Switzerland; Heerlen, Netherlands) has completed the acquisition of Adare Biome (Lawrenceville, NJ), a developer of postbiotic ingredients, for €275 million. The acquisition enhances DSM-Firmenich’s presence in several markets, including early-life nutrition, medical nutrition, and the microbiome market for pet health and animal feed.
Specifically, DSM-Firmenich notes that through its B2C group i-Health, the company plans to expand the reach of Adare Biome’s Lactéol postbiotic supplement for relieving stomach upset.
“The Adare Biome teams will greatly help in driving our ‘Health from the Gut’ strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals,” stated Philip Eykerman, president of Health, Nutrition, & Care at DSM-Firmenich, in a press release.
The company calls postbiotics “the next wave of opportunity in the gut health market,” stating that postbiotic ingredients offer longer shelf-life and broader application possibilities compared to probiotics.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
